Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

BACKGROUND: Androgen suppression is a central component of prostate cancer management but causes substantial long-term toxicity. Transdermal administration of oestradiol (tE2) circumvents first-pass hepatic metabolism and, therefore, should avoid the cardiovascular toxicity seen with oral oestrogen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet
Hlavní autoři: Langley, Ruth E, Gilbert, Duncan C, Duong, Trinh, Clarke, Noel W, Nankivell, Matthew, Rosen, Stuart D, Mangar, Stephen, Macnair, Archie, Sundaram, Subramanian Kanaga, Laniado, Marc E, Dixit, Sanjay, Madaan, Sanjeev, Manetta, Caroline, Pope, Alvan, Scrase, Christopher D, Mckay, Stephen, Muazzam, Iqtedar A, Collins, Gerald N, Worlding, Jane, Williams, Simon T, Paez, Edgar, Robinson, Angus, McFarlane, Jonathan, Deighan, John V, Marshall, John, Forcat, Silvia, Weiss, Melanie, Kockelbergh, Roger, Alhasso, Abdulla, Kynaston, Howard, Parmar, Mahesh
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614681/
https://ncbi.nlm.nih.gov/pubmed/33581820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(21)00100-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky